Top Page
Dr Reddy's Laboratories
(NYSE:RDY)
Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)
Dr Reddy's Laboratories Business Overview & Revenue Model
Dr Reddy's Laboratories Earnings Call Summary
Dr Reddy's Laboratories Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 860.40B | 325.54B | 279.16B | 245.88B | 214.39B | 2.56B |
| Gross Profit | 482.44B | 190.43B | 163.61B | 139.34B | 113.84B | 1.30B |
| EBITDA | 245.60B | 96.67B | 88.42B | 74.43B | 45.08B | 534.77M |
| Net Income | 145.99B | 56.54B | 55.68B | 45.07B | 23.57B | 232.21M |
Balance Sheet | ||||||
| Total Assets | 542.00B | 492.99B | 387.52B | 321.85B | 292.83B | 3.63B |
| Cash, Cash Equivalents and Short-Term Investments | 69.81B | 57.91B | 81.47B | 61.80B | 44.37B | 472.87M |
| Total Debt | 58.54B | 46.77B | 20.02B | 13.47B | 33.84B | 414.53M |
| Total Liabilities | 179.92B | 155.82B | 106.97B | 90.86B | 102.30B | 1.26B |
| Stockholders Equity | 358.49B | 333.39B | 280.55B | 230.99B | 190.53B | 2.37B |
Cash Flow | ||||||
| Free Cash Flow | 47.82B | 12.03B | 18.00B | 40.01B | 9.06B | 23.14B |
| Operating Cash Flow | 148.78B | 46.43B | 45.43B | 58.88B | 28.11B | 35.70B |
| Investing Cash Flow | -114.07B | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B |
| Financing Cash Flow | -37.26B | 18.91B | -3.76B | -26.86B | -2.42B | -298.00M |
Dr Reddy's Laboratories Technical Analysis
Dr Reddy's Laboratories Risk Analysis
Dr Reddy's Laboratories Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $15.43B | 36.49 | 14.96% | ― | 19.61% | 11.36% | |
73 Outperform | $11.73B | 17.25 | 17.72% | 0.65% | 10.63% | 6.35% | |
63 Neutral | $34.12B | 48.65 | 10.77% | ― | -0.25% | ― | |
60 Neutral | $13.36B | ― | -21.09% | 4.12% | -6.40% | -320.23% | |
58 Neutral | $3.56B | 788.19 | ― | ― | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.81B | -34.88 | -0.65% | 8.83% | -2.55% | 66.00% |
Dr Reddy's Laboratories Corporate Events
On December 8, 2025, Dr. Reddy’s Laboratories announced a strategic collaboration and exclusive licensing agreement with Immutep SAS to develop and commercialize Eftilagimod Alfa, a novel cancer immunotherapy, outside North America, Europe, Japan, and Greater China. This agreement allows Dr. Reddy’s to expand its oncology portfolio by leveraging its market access and expertise to advance Eftilagimod Alfa’s development, while Immutep will receive an upfront payment of USD 20 million and potential milestone payments. The collaboration underscores Dr. Reddy’s commitment to delivering innovative cancer treatments and positions the company to enhance its impact in global oncology markets.
Dr. Reddy’s Laboratories announced its participation in an investor conference organized by Bank of America in Singapore on December 8-9, 2025. This engagement is part of the company’s ongoing efforts to maintain transparency and communication with its investors, potentially impacting its market perception and stakeholder relations.
On November 28, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Nomura in Tokyo, Japan, scheduled for December 4-5, 2025. This engagement underscores the company’s proactive approach in maintaining transparency and fostering relationships with institutional investors, potentially impacting its market perception and stakeholder confidence.
Dr. Reddy’s Laboratories announced on November 24, 2025, that it has received European Commission approval for AVT03, a biosimilar of Prolia® and Xgeva®, which are used to treat osteoporosis and prevent bone complications in cancer patients. This approval, based on comprehensive evidence and clinical trials, allows Dr. Reddy’s to market AVT03 across EU and EEA countries, enhancing its position in the biosimilars market and potentially increasing its market share in Europe and the US, where it holds exclusive commercialization rights.
Dr. Reddy’s Laboratories announced its participation in several investor conferences scheduled for late November 2025. These meetings, organized by Investec, Citi, and HSBC, will take place in Mumbai, Hyderabad, and Hong Kong, respectively, and involve in-person group meetings with institutional investors. The participation in these conferences underscores Dr. Reddy’s commitment to engaging with investors and providing updates on its strategic initiatives, potentially impacting its market perception and investor relations.
On November 17, 2025, Dr. Reddy’s Laboratories announced its participation in an investor conference organized by JM Financial, scheduled for November 21, 2025, in Mumbai. This meeting, which will be conducted in person, aims to engage with investor groups and provide insights into the company’s operations and strategies. The event is significant for stakeholders as it reflects the company’s proactive approach in maintaining transparency and fostering investor relations.
On November 14, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at their API facility in Srikakulam, Andhra Pradesh, with zero observations. This successful inspection underscores the company’s commitment to maintaining high-quality standards in its manufacturing processes, potentially strengthening its position in the global pharmaceutical market.
On November 13, 2025, Dr. Reddy’s Laboratories announced the allotment of 7,430 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move reflects the company’s commitment to employee engagement and retention, potentially enhancing its operational efficiency and stakeholder value.
Dr. Reddy’s Laboratories announced the resignation of Mr. Jayanth Sridhar, the Global Head of Biologics, effective January 31, 2026. This change in senior management is part of the company’s ongoing adjustments to its leadership team, which could impact its strategic direction in the biologics sector.
On October 29, 2025, Dr. Reddy’s Laboratories received a Notice of Non-Compliance from the Pharmaceutical Drugs Directorate in Canada concerning their Abbreviated New Drug Submission for Semaglutide Injection. The notice requests additional information and clarifications, which the company plans to address promptly. Despite this setback, Dr. Reddy’s remains confident in the quality and safety of their product and is committed to making it available in Canada and other markets as soon as possible. The company appreciates the support of its stakeholders and will provide further updates when appropriate.
On October 25, 2025, Dr. Reddy’s Laboratories announced the availability of audio recordings from their earnings call conducted on October 24, 2025. This call covered the financial results for the quarter ending September 30, 2025. The release of these recordings is part of the company’s commitment to transparency and regulatory compliance, providing stakeholders with insights into their financial performance and strategic direction.
On October 25, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025. These results were advertised in the Financial Express and Andhra Prabha newspapers. This disclosure is part of the company’s compliance with the Securities and Exchange Board of India’s regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.
Dr. Reddy’s Laboratories has released its unaudited financial results for the second quarter and half-year ending September 30, 2025. This announcement, made on October 24, 2025, provides stakeholders with insights into the company’s financial performance during this period, potentially impacting its market positioning and investor relations.
Dr. Reddy’s Laboratories announced on October 24, 2025, that Mr. Sanjay Sharma, the Global Head of Operations, will take on additional responsibilities as the Chief Human Resources Officer (CHRO) effective December 1, 2025. This decision follows the resignation of Ms. Archana Bhaskar, the current CHRO, effective November 30, 2025. Mr. Sharma, with extensive experience in the FMCG and Pharmaceuticals industry, is expected to bring significant expertise to his expanded role, potentially impacting the company’s strategic direction and operational efficiency.
On October 24, 2025, Dr. Reddy’s Laboratories announced the approval of its unaudited financial results for the quarter and half-year ending September 30, 2025, during a board meeting. The results were prepared in compliance with both International Financial Reporting Standards and Indian Accounting Standards. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.
Dr. Reddy’s Laboratories has released its quarterly report for the period ending September 30, 2025, indicating a stable financial position with no material modifications required for its interim financial statements. The report highlights the company’s adherence to International Accounting Standards and its continued focus on expanding its generic medicines business despite challenges such as price erosion and regulatory hurdles. The review by Ernst & Young Associates LLP confirms the reliability of the financial data presented, reinforcing stakeholder confidence in the company’s financial health and operational strategies.
Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and six months ending September 30, 2025, on October 24, 2025, following a board meeting. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss the company’s financial performance. This announcement is significant for stakeholders as it provides insights into the company’s recent financial health and strategic direction.
On September 22, 2025, Dr. Reddy’s Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® and Xgeva®, in European markets. This development is a significant step for Dr. Reddy’s as it strengthens their position in the biosimilars market, potentially expanding their reach in Europe and the UK, and offering new treatment options under the tradenames Acvybra® and Xbonzy® upon approval.
Dr. Reddy’s Laboratories has announced a Board meeting scheduled for October 24, 2025, to review and approve the company’s unaudited financial results for the quarter ending September 30, 2025. In compliance with SEBI regulations, the company will close its trading window from September 24 to October 26, 2025, to prevent insider trading. This announcement is significant for stakeholders as it outlines the company’s commitment to transparency and regulatory compliance, which may impact investor confidence and market performance.
On September 17, 2025, Dr. Reddy’s Laboratories announced the transfer of 20.58% of its equity shares by its promoters to private family trusts. This move, involving the transfer of shares by Satish Reddy Kallam and G V Prasad to the VSD Family Trust and GVP Family Trust respectively, is part of a succession planning strategy. The transfer, which was facilitated by an exemption from SEBI, does not alter the management or control of the company, ensuring stability for stakeholders.
On September 16, 2025, Dr. Reddy’s Laboratories announced the launch of Tegoprazan, a novel potassium-competitive acid blocker, in India under the brand name PCAB®. This launch follows their 2022 partnership with South Korea’s HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets. Tegoprazan is designed to treat acid-related gastrointestinal diseases such as GERD and gastric ulcers, offering a fast onset of action and prolonged gastric pH control. With acid peptic diseases affecting approximately 38% of the Indian population, this launch aims to fill a critical gap in treatment options, potentially improving patient outcomes. Tegoprazan has already been approved in 21 countries and is undergoing registration in several others, including successful completion of a Phase-III trial in the United States.
On September 15, 2025, Dr. Reddy’s Laboratories announced the allotment of 6,475 equity shares to eligible employees as part of its Employees ADR Stock Options Scheme, 2007. This move reflects the company’s ongoing commitment to employee engagement and retention through stock-based incentives. The newly issued shares are fully paid up and rank pari passu with existing shares, contributing to the company’s total issued share capital of Rs. 83,46,14,760. This strategic allocation is expected to enhance employee motivation and align their interests with the company’s growth objectives.
On September 12, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a Pre-Approval Inspection at their biologics manufacturing facility in Bachupally, Hyderabad. The inspection, which took place from September 4 to September 12, 2025, resulted in a Form 483 with five observations. The company has committed to addressing these observations within the stipulated timeline, which is crucial for maintaining compliance and advancing their market position in the biologics sector.
On September 10, 2025, Dr. Reddy’s Laboratories announced the acquisition of the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. This acquisition, valued at USD 50.5 million, includes the STUGERON® portfolio across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. The acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) portfolio by expanding into the anti-vertigo segment, leveraging STUGERON®’s leading position in the Cinnarizine market in India. This strategic move aligns with Dr. Reddy’s broader goal of enhancing patient access and aims to reach over 1.5 billion patients by 2030.